Literature DB >> 17923237

Synthesis of anti-reverse cap analogs (ARCAs) and their applications in mRNA translation and stability.

Ewa Grudzien-Nogalska1, Janusz Stepinski, Jacek Jemielity, Joanna Zuberek, Ryszard Stolarski, Robert E Rhoads, Edward Darzynkiewicz.   

Abstract

Synthetic capped RNA transcripts produced by in vitro transcription in the presence of m(7)Gp(3)G have found a wide application in studying such processes as mRNA translation, pre-mRNA splicing, mRNA turnover, and intracellular transport of mRNA and snRNA. However, because of the presence of a 3'-OH on both m(7)Guo and Guo moieties of the cap structure, one-third to one-half of the mRNAs contain a cap incorporated in the reverse orientation. The reverse cap structures bind poorly to eIF4E, the cap binding protein, and reduce overall translational efficiency. We therefore replaced the conventional m(7)Gp(3)G cap by "anti-reverse" cap analogs (ARCAs) in which the 3'-OH of m(7)Guo moiety was substituted by 3'-deoxy or 3'-O-methyl groups, leading to m(7)3'dGp(3)G or m(2)(7,3'-O) Gp(3)G, respectively. The class of ARCAs was extended to analogs possessing an O-methyl group or deoxy group at C2' of m(7)Guo. We have also developed a series of ARCAs containing tetra- and pentaphosphates. mRNAs capped with various ARCAs were translated 1.1- to 2.6-fold more efficiently than their counterparts capped with m(7)Gp(3)G in both in vitro and in vivo systems. In a separate series, a methylene group was introduced between the alpha- and beta-, or beta- and gamma-phosphate moieties, leading to m(2)(7,3'-O)Gpp(CH2)pG and m(2)(7,3'-O)Gp(CH2)ppG. These analogs are resistant to cleavage by the decapping enzymes Dcp1/Dcp2 and DcpS, respectively. mRNA transcripts capped with m(2)(7,3'-O)Gpp(CH2)pG were more stable when introduced into cultured mammalian cells. In this chapter, we describe the synthesis of representative ARCAs and their biophysical and biochemical characterization, with emphasis on practical applications in mRNA translation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923237     DOI: 10.1016/S0076-6879(07)31011-2

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  37 in total

1.  Pervasive and cooperative deadenylation of 3'UTRs by embryonic microRNA families.

Authors:  Edlyn Wu; Caroline Thivierge; Mathieu Flamand; Geraldine Mathonnet; Ajay A Vashisht; James Wohlschlegel; Marc R Fabian; Nahum Sonenberg; Thomas F Duchaine
Journal:  Mol Cell       Date:  2010-11-24       Impact factor: 17.970

2.  Emerging therapeutics targeting mRNA translation.

Authors:  Abba Malina; John R Mills; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

3.  Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes.

Authors:  Joanna Kowalska; Anna Wypijewska del Nogal; Zbigniew M Darzynkiewicz; Janina Buck; Corina Nicola; Andreas N Kuhn; Maciej Lukaszewicz; Joanna Zuberek; Malwina Strenkowska; Marcin Ziemniak; Maciej Maciejczyk; Elzbieta Bojarska; Robert E Rhoads; Edward Darzynkiewicz; Ugur Sahin; Jacek Jemielity
Journal:  Nucleic Acids Res       Date:  2014-08-22       Impact factor: 16.971

4.  mRNA cap analogues substituted in the tetraphosphate chain with CX2: identification of O-to-CCl2 as the first bridging modification that confers resistance to decapping without impairing translation.

Authors:  Anna M Rydzik; Marcin Warminski; Pawel J Sikorski; Marek R Baranowski; Sylwia Walczak; Joanna Kowalska; Joanna Zuberek; Maciej Lukaszewicz; Elzbieta Nowak; Timothy D W Claridge; Edward Darzynkiewicz; Marcin Nowotny; Jacek Jemielity
Journal:  Nucleic Acids Res       Date:  2017-09-06       Impact factor: 16.971

5.  Modified ARCA analogs providing enhanced translational properties of capped mRNAs.

Authors:  Ilona Kocmik; Karolina Piecyk; Magdalena Rudzinska; Anna Niedzwiecka; Edward Darzynkiewicz; Renata Grzela; Marzena Jankowska-Anyszka
Journal:  Cell Cycle       Date:  2018-08-17       Impact factor: 4.534

Review 6.  Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications.

Authors:  Siddharth Patel; Avathamsa Athirasala; Paula P Menezes; N Ashwanikumar; Ting Zou; Gaurav Sahay; Luiz E Bertassoni
Journal:  Tissue Eng Part A       Date:  2018-06-07       Impact factor: 3.845

Review 7.  Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases.

Authors:  Zeljka Trepotec; Eva Lichtenegger; Christian Plank; Manish K Aneja; Carsten Rudolph
Journal:  Mol Ther       Date:  2018-12-22       Impact factor: 11.454

8.  Homodimeric anoctamin-1, but not homodimeric anoctamin-6, is activated by calcium increases mediated by the P2Y1 and P2X7 receptors.

Authors:  Michaela Stolz; Manuela Klapperstück; Thomas Kendzierski; Silvia Detro-Dassen; Anna Panning; Günther Schmalzing; Fritz Markwardt
Journal:  Pflugers Arch       Date:  2015-01-17       Impact factor: 3.657

9.  Efficient preparation and properties of mRNAs containing a fluorescent cap analog: Anthraniloyl-m(7)GpppG.

Authors:  Dilantha Gunawardana; Artem V Domashevskiy; Ken R Gayler; Dixie J Goss
Journal:  Translation (Austin)       Date:  2015-02-02

10.  mRNAs containing the histone 3' stem-loop are degraded primarily by decapping mediated by oligouridylation of the 3' end.

Authors:  Wei Su; Sergey V Slepenkov; Michael K Slevin; Shawn M Lyons; Marcin Ziemniak; Joanna Kowalska; Edward Darzynkiewicz; Jacek Jemielity; William F Marzluff; Robert E Rhoads
Journal:  RNA       Date:  2012-11-27       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.